Award
NIH Reporter #6R01AI160269-06
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by -lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Recipient
National Institute of Allergy and Infectious Diseases (NIAID)
Award Amount
$1,103,779.00
Ceiling
$1,103,779.00
Awarded
July 22, 2026
Identifier
6R01AI160269-06
Development of novel cyclic boronate inhibitors targeting penicillin-binding proteins to treat infections caused by carbapenem-resistant Enterobacterales by overcoming -lactamase resistance.
Description
The project focuses on developing cyclic boronate PBP inhibitors to combat -lactamase-mediated resistance in carbapenem-resistant Enterobacterales (CRE). The goal is to create a new intravenous therapeutic option that circumvents class-specific resistance mechanisms, with promising microbiological activity and pharmacokinetic properties.